Festival of Biologics Europe 2024 Poster
June 18, 2025
Summary:
Anti-CD20 monoclonal antibodies are mainstays in the treatment of B-cell malignancies and autoimmune diseases, but how well do we understand the full spectrum of their immune mechanisms?
In this poster presented at Festival of Biologics 2024, SeromYx Systems leverages its high-throughput Fc effector function platform to comprehensively profile the functional landscape of rituximab, ofatumumab, and obinutuzumab. Using a full-length recombinant CD20 VLP from ACROBiosystems, the study confirms known mechanisms like ADCC, ADCP, and CDC, while also uncovering previously unreported effector functions such as eosinophil and neutrophil phagocytosis.
Key insights:
- Biophysical FcγR and C1q binding strongly predicts functional outcomes
- Clear differentiation in Fc profiles across clinically approved anti-CD20 mAbs
- Novel functional findings may inform next-gen antibody engineering strategies
Author:
Shashi Jatiani, PhD.
Authors: Stefanutti E, Ramani R, Whitener B, Dang H, Bélanger S, Somasundaram L, Cortina K, De Marco A, Tam T, Chai Q, Cameroni E, Gupta R, Schmid MA, Miller JL, Zumsteg AB, Purcell LA, Drewry LL. 0. Analysis of Fc-dependent effector functions of anti-malaria circumsporozoite protein antibodies. Microbiol Spectr 0:e00863-25. Journal: Microbiology Spectrum
Antibody Engineering & Therapeutics 2025
The World Vaccine Congress Europe 2025
Festival of Biologics
The Fc-Mediated Effector Function Summit
Authors: Kaplonek P, et al. Sci Transl Med. 2022 May 18;14(645):eabm2311.
Authors: Hawman, David W. et al. eBioMedicine, Volume 115, 105698
Authors: Crescioli, S, Jatiani, S, & Moise, L, (2025). mAbs, 17(1). Journal: mAbs
Authors: Osborn, G., López-Abente, J., Adams, R. et al.
Woburn, MA / Newark, DE – October 1st, 2024 - SeromYx Systems, a cutting-edge immunology technology company, and ACROBiosystems, a leading provider for life science solutions and tools, are excited to announce the release of their joint study on the...
